Jennison Associates LLC increased its position in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT – Get Rating) by 11.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 195,036 shares of the company’s stock after acquiring an additional 20,745 shares during the period. Jennison Associates LLC […]
Adaptive Biotechnologies (NASDAQ:ADPT – Get Rating) had its target price lifted by Piper Sandler from $14.00 to $15.00 in a report released on Monday morning, The Fly reports. A number of other analysts also recently issued reports on ADPT. Credit Suisse Group reiterated an underperform rating and issued a $7.00 price target on shares of […]
Adaptive Biotechnologies Co. (NASDAQ:ADPT – Get Rating) – Investment analysts at William Blair lifted their Q2 2023 earnings estimates for Adaptive Biotechnologies in a report issued on Thursday, May 4th. William Blair analyst A. Brackmann now forecasts that the company will post earnings of ($0.31) per share for the quarter, up from their previous estimate […]
The T-Cell Therapy product candidate contains a neoantigen-specific T-cell receptor (TCR) identified and characterized through Adaptive’s TCR discovery.
Adaptive Biotechnologies (NASDAQ:ADPT – Get Rating) had its target price boosted by analysts at Piper Sandler from $14.00 to $15.00 in a note issued to investors on Monday, The Fly reports. Piper Sandler’s price objective suggests a potential upside of 134.38% from the stock’s current price. ADPT has been the subject of a number of […]